Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Hormone Refractory Breast Cancer Market by Treatment Modality (Hormone receptor-based therapy, Tumor markers therapy, Gene expression therapy, Gene mutation therapy): Global Opportunity Analysis and Industry Forecast, 2023-2032

A01149

Pages: NA

Charts: NA

Tables: NA

Breast cancer is one of the most common type of malignant cancers, which is prevalent in women above 40 years. As per World Health Organization (WHO) estimates, breast cancer accounted for around 521,000 deaths globally in 2012. Generally, hormone therapies are used for treating breast cancer, which subsequently leads to resistance after continuous use of hormone therapy. This resistance towards hormone therapy is termed as hormone refractory breast cancer. Hence, there is an increasing need for the effective treatment in hormone refractory breast cancer market. The market holds immense future potential, as there is no standard therapy, approved for hormone refractory breast cancer. However, there are rising hopes to get approved therapies in near future as drugs such as trastuzumab and everolimus, alone or in combination, are under development for the effective treatment of hormone refractory breast cancers.

The key factors driving growth of this market include, increasing global incidences of breast cancers, uprising prevalence rates of hormone refractory breast cancers, ageing population, demands of advanced therapeutics and increasing R&D investment on breast cancer drugs. The factors restraining the market growth are the social stigma related with breast cancer examinations, and insufficient advanced chemotherapeutic treatments. Substantial number of new chemical entities (NCEs) in different phases of clinical trials would emerge as a potential opportunity in the global hormone refractory breast cancer market.

The global market for hormone refractory breast cancer market is segmented on the basis of treatment modality and geography. The type of treatment modalities considered in this report include: hormone receptor-based therapy, tumor markers therapy, and gene expression therapy. Geographically, the market is segmented into four regions namely North America, Europe, Asia Pacific, and LAMEA. North America and Europe would lead the market owing to large number of affected population along with a high percentage of geriatric population and a significant number of research and drug development activities. The key market players considered in the report include AstraZeneca plc, Bluefish Pharmaceuticals AB, AmpliMed Corporation, Bioenvision Limited, F. Hoffmann-La Roche Ltd., Neopharm Ltd., NeoCorp GmbH, and Boehringer Ingelheim GmbH.

KEY MARKET BENEFITS

  • The analysis, made in this report, helps in understanding the strategies adopted by various companies for gaining market share in hormone refractory breast cancer market
  • The report provides the quantitative analysis of the current market and estimations that assists in identifying the prevailing market opportunities to capitalize on
  • This report provides a comprehensive analysis of factors that drive and restrict the growth of the hormone refractory breast cancer market
  • Detailed study of the strategies of key leaders, partnerships, and acquisitions in the global hormone refractory breast cancer market would be informative for professionals in the corporate sector
  • Pin-point analysis of geographic segments helps to identify opportunities for growth within the hormone refractory breast cancer market
  • Identification of key investment pockets for hormone refractory breast cancer market provide strategic assistance to decision makers
  • An analysis for the market attractiveness has been included for therapeutics, devices, and geographic regions along with a detailed analysis of factors responsible for the rapid growth of the market segments

 Key Market Segments

  • By Treatment Modality
    • Hormone receptor-based therapy
    • Tumor markers therapy
    • Gene expression therapy
    • Gene mutation therapy
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • Rest of LAMEA

 
Key Market Players

  • Bioenvision Limited
  • AmpliMed Corporation
  • AstraZeneca plc
  • Neopharm Ltd.
  • Teva Pharmaceutical Industries Ltd,
  • Boehringer Ingelheim GmbH.
  • Eli Lilly and Company
  • Bluefish Pharmaceuticals AB
  • NeoCorp GmbH
  • F. Hoffmann-La Roche Ltd.

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: HORMONE REFRACTORY BREAST CANCER MARKET, BY TREATMENT MODALITY

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Treatment Modality

    • 4.2. Hormone Receptor-based Therapy

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Tumor Markers Therapy

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Gene Expression Therapy

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Gene Mutation Therapy

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

  • CHAPTER 5: HORMONE REFRACTORY BREAST CANCER MARKET, BY REGION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Region

    • 5.2. North America

      • 5.2.1. Key Market Trends and Opportunities

      • 5.2.2. Market Size and Forecast, By Treatment Modality

      • 5.2.3. Market Size and Forecast, By Country

      • 5.2.4. U.S. Hormone Refractory Breast Cancer Market

        • 5.2.4.1. Market Size and Forecast, By Treatment Modality

      • 5.2.5. Canada Hormone Refractory Breast Cancer Market

        • 5.2.5.1. Market Size and Forecast, By Treatment Modality

      • 5.2.6. Mexico Hormone Refractory Breast Cancer Market

        • 5.2.6.1. Market Size and Forecast, By Treatment Modality

    • 5.3. Europe

      • 5.3.1. Key Market Trends and Opportunities

      • 5.3.2. Market Size and Forecast, By Treatment Modality

      • 5.3.3. Market Size and Forecast, By Country

      • 5.3.4. France Hormone Refractory Breast Cancer Market

        • 5.3.4.1. Market Size and Forecast, By Treatment Modality

      • 5.3.5. Germany Hormone Refractory Breast Cancer Market

        • 5.3.5.1. Market Size and Forecast, By Treatment Modality

      • 5.3.6. Italy Hormone Refractory Breast Cancer Market

        • 5.3.6.1. Market Size and Forecast, By Treatment Modality

      • 5.3.7. Spain Hormone Refractory Breast Cancer Market

        • 5.3.7.1. Market Size and Forecast, By Treatment Modality

      • 5.3.8. UK Hormone Refractory Breast Cancer Market

        • 5.3.8.1. Market Size and Forecast, By Treatment Modality

      • 5.3.9. Russia Hormone Refractory Breast Cancer Market

        • 5.3.9.1. Market Size and Forecast, By Treatment Modality

      • 5.3.10. Rest Of Europe Hormone Refractory Breast Cancer Market

        • 5.3.10.1. Market Size and Forecast, By Treatment Modality

    • 5.4. Asia-Pacific

      • 5.4.1. Key Market Trends and Opportunities

      • 5.4.2. Market Size and Forecast, By Treatment Modality

      • 5.4.3. Market Size and Forecast, By Country

      • 5.4.4. China Hormone Refractory Breast Cancer Market

        • 5.4.4.1. Market Size and Forecast, By Treatment Modality

      • 5.4.5. Japan Hormone Refractory Breast Cancer Market

        • 5.4.5.1. Market Size and Forecast, By Treatment Modality

      • 5.4.6. India Hormone Refractory Breast Cancer Market

        • 5.4.6.1. Market Size and Forecast, By Treatment Modality

      • 5.4.7. South Korea Hormone Refractory Breast Cancer Market

        • 5.4.7.1. Market Size and Forecast, By Treatment Modality

      • 5.4.8. Australia Hormone Refractory Breast Cancer Market

        • 5.4.8.1. Market Size and Forecast, By Treatment Modality

      • 5.4.9. Thailand Hormone Refractory Breast Cancer Market

        • 5.4.9.1. Market Size and Forecast, By Treatment Modality

      • 5.4.10. Malaysia Hormone Refractory Breast Cancer Market

        • 5.4.10.1. Market Size and Forecast, By Treatment Modality

      • 5.4.11. Indonesia Hormone Refractory Breast Cancer Market

        • 5.4.11.1. Market Size and Forecast, By Treatment Modality

      • 5.4.12. Rest of Asia Pacific Hormone Refractory Breast Cancer Market

        • 5.4.12.1. Market Size and Forecast, By Treatment Modality

    • 5.5. LAMEA

      • 5.5.1. Key Market Trends and Opportunities

      • 5.5.2. Market Size and Forecast, By Treatment Modality

      • 5.5.3. Market Size and Forecast, By Country

      • 5.5.4. Brazil Hormone Refractory Breast Cancer Market

        • 5.5.4.1. Market Size and Forecast, By Treatment Modality

      • 5.5.5. South Africa Hormone Refractory Breast Cancer Market

        • 5.5.5.1. Market Size and Forecast, By Treatment Modality

      • 5.5.6. Saudi Arabia Hormone Refractory Breast Cancer Market

        • 5.5.6.1. Market Size and Forecast, By Treatment Modality

      • 5.5.7. UAE Hormone Refractory Breast Cancer Market

        • 5.5.7.1. Market Size and Forecast, By Treatment Modality

      • 5.5.8. Argentina Hormone Refractory Breast Cancer Market

        • 5.5.8.1. Market Size and Forecast, By Treatment Modality

      • 5.5.9. Rest of LAMEA Hormone Refractory Breast Cancer Market

        • 5.5.9.1. Market Size and Forecast, By Treatment Modality

  • CHAPTER 6: COMPETITIVE LANDSCAPE

    • 6.1. Introduction

    • 6.2. Top Winning Strategies

    • 6.3. Product Mapping Of Top 10 Player

    • 6.4. Competitive Dashboard

    • 6.5. Competitive Heatmap

    • 6.6. Top Player Positioning, 2024

  • CHAPTER 7: COMPANY PROFILES

    • 7.1. AstraZeneca Plc

      • 7.1.1. Company Overview

      • 7.1.2. Key Executives

      • 7.1.3. Company Snapshot

      • 7.1.4. Operating Business Segments

      • 7.1.5. Product Portfolio

      • 7.1.6. Business Performance

      • 7.1.7. Key Strategic Moves and Developments

    • 7.2. Bluefish Pharmaceuticals AB

      • 7.2.1. Company Overview

      • 7.2.2. Key Executives

      • 7.2.3. Company Snapshot

      • 7.2.4. Operating Business Segments

      • 7.2.5. Product Portfolio

      • 7.2.6. Business Performance

      • 7.2.7. Key Strategic Moves and Developments

    • 7.3. AmpliMed Corporation

      • 7.3.1. Company Overview

      • 7.3.2. Key Executives

      • 7.3.3. Company Snapshot

      • 7.3.4. Operating Business Segments

      • 7.3.5. Product Portfolio

      • 7.3.6. Business Performance

      • 7.3.7. Key Strategic Moves and Developments

    • 7.4. Bioenvision Limited

      • 7.4.1. Company Overview

      • 7.4.2. Key Executives

      • 7.4.3. Company Snapshot

      • 7.4.4. Operating Business Segments

      • 7.4.5. Product Portfolio

      • 7.4.6. Business Performance

      • 7.4.7. Key Strategic Moves and Developments

    • 7.5. F. Hoffmann-La Roche Ltd.

      • 7.5.1. Company Overview

      • 7.5.2. Key Executives

      • 7.5.3. Company Snapshot

      • 7.5.4. Operating Business Segments

      • 7.5.5. Product Portfolio

      • 7.5.6. Business Performance

      • 7.5.7. Key Strategic Moves and Developments

    • 7.6. Neopharm Ltd.

      • 7.6.1. Company Overview

      • 7.6.2. Key Executives

      • 7.6.3. Company Snapshot

      • 7.6.4. Operating Business Segments

      • 7.6.5. Product Portfolio

      • 7.6.6. Business Performance

      • 7.6.7. Key Strategic Moves and Developments

    • 7.7. NeoCorp GmbH

      • 7.7.1. Company Overview

      • 7.7.2. Key Executives

      • 7.7.3. Company Snapshot

      • 7.7.4. Operating Business Segments

      • 7.7.5. Product Portfolio

      • 7.7.6. Business Performance

      • 7.7.7. Key Strategic Moves and Developments

    • 7.8. Boehringer Ingelheim GmbH.

      • 7.8.1. Company Overview

      • 7.8.2. Key Executives

      • 7.8.3. Company Snapshot

      • 7.8.4. Operating Business Segments

      • 7.8.5. Product Portfolio

      • 7.8.6. Business Performance

      • 7.8.7. Key Strategic Moves and Developments

    • 7.9. Eli Lilly And Company

      • 7.9.1. Company Overview

      • 7.9.2. Key Executives

      • 7.9.3. Company Snapshot

      • 7.9.4. Operating Business Segments

      • 7.9.5. Product Portfolio

      • 7.9.6. Business Performance

      • 7.9.7. Key Strategic Moves and Developments

    • 7.10. Teva Pharmaceutical Industries Ltd,

      • 7.10.1. Company Overview

      • 7.10.2. Key Executives

      • 7.10.3. Company Snapshot

      • 7.10.4. Operating Business Segments

      • 7.10.5. Product Portfolio

      • 7.10.6. Business Performance

      • 7.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL HORMONE REFRACTORY BREAST CANCER MARKET, BY TREATMENT MODALITY, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL HORMONE REFRACTORY BREAST CANCER MARKET FOR HORMONE RECEPTOR-BASED THERAPY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL HORMONE REFRACTORY BREAST CANCER MARKET FOR TUMOR MARKERS THERAPY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL HORMONE REFRACTORY BREAST CANCER MARKET FOR GENE EXPRESSION THERAPY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL HORMONE REFRACTORY BREAST CANCER MARKET FOR GENE MUTATION THERAPY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL HORMONE REFRACTORY BREAST CANCER MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. NORTH AMERICA HORMONE REFRACTORY BREAST CANCER, BY REGION, 2025-2033 ($MILLION)
  • TABLE 8. NORTH AMERICA HORMONE REFRACTORY BREAST CANCER, BY TREATMENT MODALITY, 2025-2033 ($MILLION)
  • TABLE 9. U.S. HORMONE REFRACTORY BREAST CANCER, BY TREATMENT MODALITY, 2025-2033 ($MILLION)
  • TABLE 10. CANADA HORMONE REFRACTORY BREAST CANCER, BY TREATMENT MODALITY, 2025-2033 ($MILLION)
  • TABLE 11. MEXICO HORMONE REFRACTORY BREAST CANCER, BY TREATMENT MODALITY, 2025-2033 ($MILLION)
  • TABLE 12. EUROPE HORMONE REFRACTORY BREAST CANCER, BY REGION, 2025-2033 ($MILLION)
  • TABLE 13. EUROPE HORMONE REFRACTORY BREAST CANCER, BY TREATMENT MODALITY, 2025-2033 ($MILLION)
  • TABLE 14. FRANCE HORMONE REFRACTORY BREAST CANCER, BY TREATMENT MODALITY, 2025-2033 ($MILLION)
  • TABLE 15. GERMANY HORMONE REFRACTORY BREAST CANCER, BY TREATMENT MODALITY, 2025-2033 ($MILLION)
  • TABLE 16. ITALY HORMONE REFRACTORY BREAST CANCER, BY TREATMENT MODALITY, 2025-2033 ($MILLION)
  • TABLE 17. SPAIN HORMONE REFRACTORY BREAST CANCER, BY TREATMENT MODALITY, 2025-2033 ($MILLION)
  • TABLE 18. UK HORMONE REFRACTORY BREAST CANCER, BY TREATMENT MODALITY, 2025-2033 ($MILLION)
  • TABLE 19. RUSSIA HORMONE REFRACTORY BREAST CANCER, BY TREATMENT MODALITY, 2025-2033 ($MILLION)
  • TABLE 20. REST OF EUROPE HORMONE REFRACTORY BREAST CANCER, BY TREATMENT MODALITY, 2025-2033 ($MILLION)
  • TABLE 21. ASIA-PACIFIC HORMONE REFRACTORY BREAST CANCER, BY REGION, 2025-2033 ($MILLION)
  • TABLE 22. ASIA-PACIFIC HORMONE REFRACTORY BREAST CANCER, BY TREATMENT MODALITY, 2025-2033 ($MILLION)
  • TABLE 23. CHINA HORMONE REFRACTORY BREAST CANCER, BY TREATMENT MODALITY, 2025-2033 ($MILLION)
  • TABLE 24. JAPAN HORMONE REFRACTORY BREAST CANCER, BY TREATMENT MODALITY, 2025-2033 ($MILLION)
  • TABLE 25. INDIA HORMONE REFRACTORY BREAST CANCER, BY TREATMENT MODALITY, 2025-2033 ($MILLION)
  • TABLE 26. SOUTH KOREA HORMONE REFRACTORY BREAST CANCER, BY TREATMENT MODALITY, 2025-2033 ($MILLION)
  • TABLE 27. AUSTRALIA HORMONE REFRACTORY BREAST CANCER, BY TREATMENT MODALITY, 2025-2033 ($MILLION)
  • TABLE 28. THAILAND HORMONE REFRACTORY BREAST CANCER, BY TREATMENT MODALITY, 2025-2033 ($MILLION)
  • TABLE 29. MALAYSIA HORMONE REFRACTORY BREAST CANCER, BY TREATMENT MODALITY, 2025-2033 ($MILLION)
  • TABLE 30. INDONESIA HORMONE REFRACTORY BREAST CANCER, BY TREATMENT MODALITY, 2025-2033 ($MILLION)
  • TABLE 31. REST OF ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER, BY TREATMENT MODALITY, 2025-2033 ($MILLION)
  • TABLE 32. LAMEA HORMONE REFRACTORY BREAST CANCER, BY REGION, 2025-2033 ($MILLION)
  • TABLE 33. LAMEA HORMONE REFRACTORY BREAST CANCER, BY TREATMENT MODALITY, 2025-2033 ($MILLION)
  • TABLE 34. BRAZIL HORMONE REFRACTORY BREAST CANCER, BY TREATMENT MODALITY, 2025-2033 ($MILLION)
  • TABLE 35. SOUTH AFRICA HORMONE REFRACTORY BREAST CANCER, BY TREATMENT MODALITY, 2025-2033 ($MILLION)
  • TABLE 36. SAUDI ARABIA HORMONE REFRACTORY BREAST CANCER, BY TREATMENT MODALITY, 2025-2033 ($MILLION)
  • TABLE 37. UAE HORMONE REFRACTORY BREAST CANCER, BY TREATMENT MODALITY, 2025-2033 ($MILLION)
  • TABLE 38. ARGENTINA HORMONE REFRACTORY BREAST CANCER, BY TREATMENT MODALITY, 2025-2033 ($MILLION)
  • TABLE 39. REST OF LAMEA HORMONE REFRACTORY BREAST CANCER, BY TREATMENT MODALITY, 2025-2033 ($MILLION)
  • TABLE 40. ASTRAZENECA PLC: KEY EXECUTIVES
  • TABLE 41. ASTRAZENECA PLC: COMPANY SNAPSHOT
  • TABLE 42. ASTRAZENECA PLC: OPERATING SEGMENTS
  • TABLE 43. ASTRAZENECA PLC: PRODUCT PORTFOLIO
  • TABLE 44. ASTRAZENECA PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 45. BLUEFISH PHARMACEUTICALS AB: KEY EXECUTIVES
  • TABLE 46. BLUEFISH PHARMACEUTICALS AB: COMPANY SNAPSHOT
  • TABLE 47. BLUEFISH PHARMACEUTICALS AB: OPERATING SEGMENTS
  • TABLE 48. BLUEFISH PHARMACEUTICALS AB: PRODUCT PORTFOLIO
  • TABLE 49. BLUEFISH PHARMACEUTICALS AB: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 50. AMPLIMED CORPORATION: KEY EXECUTIVES
  • TABLE 51. AMPLIMED CORPORATION: COMPANY SNAPSHOT
  • TABLE 52. AMPLIMED CORPORATION: OPERATING SEGMENTS
  • TABLE 53. AMPLIMED CORPORATION: PRODUCT PORTFOLIO
  • TABLE 54. AMPLIMED CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 55. BIOENVISION LIMITED: KEY EXECUTIVES
  • TABLE 56. BIOENVISION LIMITED: COMPANY SNAPSHOT
  • TABLE 57. BIOENVISION LIMITED: OPERATING SEGMENTS
  • TABLE 58. BIOENVISION LIMITED: PRODUCT PORTFOLIO
  • TABLE 59. BIOENVISION LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 60. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
  • TABLE 61. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
  • TABLE 62. F. HOFFMANN-LA ROCHE LTD.: OPERATING SEGMENTS
  • TABLE 63. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
  • TABLE 64. F. HOFFMANN-LA ROCHE LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 65. NEOPHARM LTD.: KEY EXECUTIVES
  • TABLE 66. NEOPHARM LTD.: COMPANY SNAPSHOT
  • TABLE 67. NEOPHARM LTD.: OPERATING SEGMENTS
  • TABLE 68. NEOPHARM LTD.: PRODUCT PORTFOLIO
  • TABLE 69. NEOPHARM LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 70. NEOCORP GMBH: KEY EXECUTIVES
  • TABLE 71. NEOCORP GMBH: COMPANY SNAPSHOT
  • TABLE 72. NEOCORP GMBH: OPERATING SEGMENTS
  • TABLE 73. NEOCORP GMBH: PRODUCT PORTFOLIO
  • TABLE 74. NEOCORP GMBH: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 75. BOEHRINGER INGELHEIM GMBH.: KEY EXECUTIVES
  • TABLE 76. BOEHRINGER INGELHEIM GMBH.: COMPANY SNAPSHOT
  • TABLE 77. BOEHRINGER INGELHEIM GMBH.: OPERATING SEGMENTS
  • TABLE 78. BOEHRINGER INGELHEIM GMBH.: PRODUCT PORTFOLIO
  • TABLE 79. BOEHRINGER INGELHEIM GMBH.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 80. ELI LILLY AND COMPANY: KEY EXECUTIVES
  • TABLE 81. ELI LILLY AND COMPANY: COMPANY SNAPSHOT
  • TABLE 82. ELI LILLY AND COMPANY: OPERATING SEGMENTS
  • TABLE 83. ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
  • TABLE 84. ELI LILLY AND COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 85. TEVA PHARMACEUTICAL INDUSTRIES LTD,: KEY EXECUTIVES
  • TABLE 86. TEVA PHARMACEUTICAL INDUSTRIES LTD,: COMPANY SNAPSHOT
  • TABLE 87. TEVA PHARMACEUTICAL INDUSTRIES LTD,: OPERATING SEGMENTS
  • TABLE 88. TEVA PHARMACEUTICAL INDUSTRIES LTD,: PRODUCT PORTFOLIO
  • TABLE 89. TEVA PHARMACEUTICAL INDUSTRIES LTD,: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL HORMONE REFRACTORY BREAST CANCER MARKET SEGMENTATION
  • FIGURE 2. GLOBAL HORMONE REFRACTORY BREAST CANCER MARKET
  • FIGURE 3. SEGMENTATION HORMONE REFRACTORY BREAST CANCER MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN HORMONE REFRACTORY BREAST CANCER MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALHORMONE REFRACTORY BREAST CANCER MARKET
  • FIGURE 11. HORMONE REFRACTORY BREAST CANCER MARKET SEGMENTATION, BY BY TREATMENT MODALITY
  • FIGURE 12. HORMONE REFRACTORY BREAST CANCER MARKET FOR HORMONE RECEPTOR-BASED THERAPY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. HORMONE REFRACTORY BREAST CANCER MARKET FOR TUMOR MARKERS THERAPY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. HORMONE REFRACTORY BREAST CANCER MARKET FOR GENE EXPRESSION THERAPY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 15. HORMONE REFRACTORY BREAST CANCER MARKET FOR GENE MUTATION THERAPY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 16. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 17. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 18. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 19. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 20. COMPETITIVE DASHBOARD
  • FIGURE 21. COMPETITIVE HEATMAP: HORMONE REFRACTORY BREAST CANCER MARKET
  • FIGURE 22. TOP PLAYER POSITIONING, 2024
  • FIGURE 23. ASTRAZENECA PLC: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 24. ASTRAZENECA PLC: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 25. ASTRAZENECA PLC: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 26. BLUEFISH PHARMACEUTICALS AB: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 27. BLUEFISH PHARMACEUTICALS AB: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 28. BLUEFISH PHARMACEUTICALS AB: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 29. AMPLIMED CORPORATION: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 30. AMPLIMED CORPORATION: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 31. AMPLIMED CORPORATION: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 32. BIOENVISION LIMITED: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 33. BIOENVISION LIMITED: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 34. BIOENVISION LIMITED: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 35. F. HOFFMANN-LA ROCHE LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 36. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 37. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 38. NEOPHARM LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 39. NEOPHARM LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 40. NEOPHARM LTD.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 41. NEOCORP GMBH: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 42. NEOCORP GMBH: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 43. NEOCORP GMBH: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 44. BOEHRINGER INGELHEIM GMBH.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 45. BOEHRINGER INGELHEIM GMBH.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 46. BOEHRINGER INGELHEIM GMBH.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 47. ELI LILLY AND COMPANY: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 48. ELI LILLY AND COMPANY: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 49. ELI LILLY AND COMPANY: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 50. TEVA PHARMACEUTICAL INDUSTRIES LTD,: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 51. TEVA PHARMACEUTICAL INDUSTRIES LTD,: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 52. TEVA PHARMACEUTICAL INDUSTRIES LTD,: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Hormone Refractory Breast Cancer Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved